I Love Lund (LOVE) investor relations material

Executive summary

• Q3 net loss was SEK 151k versus SEK 76k; nine-month loss narrowed to SEK 73k from SEK 4.10m, chiefly as financial items turned positive.

• The diversified portfolio comprised about 40 companies; a SEK 1.5m investment in Aligned Bio was the quarter’s new investment.

• Management described portfolio news and the investment pipeline as improving, while noting that portfolio-company progress may not appear in near-term accounts.

Financial highlights

• Q3 revenue was SEK 0; operating expenses were SEK 712k and operating loss SEK 712k, versus SEK 678k loss a year earlier.

• Q3 net financial income was SEK 561k, including net impairment reversals of SEK 3k versus SEK 753k of net impairments in Q3 2025; loss after financial items was SEK 151k.

• 9M operating loss was SEK 2.37m versus SEK 2.27m; net financial income was SEK 2.30m versus a SEK 1.83m loss, leaving a SEK 73k net loss versus SEK 4.10m.

• Cash and cash equivalents were SEK 2.28m at September 30, up from SEK 489k at year-end 2025; 9M cash flow was positive SEK 1.79m.

Outlook and guidance

• No formal forecasts are issued; management said the investment pipeline improved during the year and portfolio companies’ news flow showed more confidence than a year earlier.

• Reported portfolio-company opportunities included improved sales expectations and fundraising prospects, with better commercial activity at several holdings.

• Upcoming reporting dates are the FY 2026 year-end report on January 22, 2027, and the 2026 annual report on February 12, 2027.